You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: February 18, 2020

DrugPatentWatch Database Preview

Patent: 9,241,931

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,241,931
Title:Compound useful for the treatment of degenerative and inflammatory diseases
Abstract: A pyrazolopyridine compound according to Formula I, able to inhibit JAK is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant JAK activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6. ##STR00001##
Inventor(s): Menet; Christel Jeanne Marie (Mechelen, BE), Hodges; Alastair James (Essex, GB), Vater; Huw David (Essex, GB)
Assignee: GALAPAGOS NV (Mechelen, BE)
Application Number:14/457,071
Patent Claims:see list of patent claims

Details for Patent 9,241,931

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial GALAPAGOS NV (Mechelen, BE) 2031-04-28 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial GALAPAGOS NV (Mechelen, BE) 2031-04-28 RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial GALAPAGOS NV (Mechelen, BE) 2031-04-28 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial GALAPAGOS NV (Mechelen, BE) 2031-04-28 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.